Clinical trials: CYP19
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Breast Cancer, Joint Pain
Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer
Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint pain/stiffness associated with aromatase inhibitors.
- Trial name
- NCT00691678
- Testing
- Chondroitin, Glucosamine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Dawn L. Hershman
Breast Cancer
Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00238290
- Testing
- Trastuzumab + Letrozole
- Where
- 14 sites in Switzerland
- Volunteers
- 13 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer
Purpose:Acupuncture for arthralgia induced by aromatase inhibitors in patients with breast cancer associated with screening of SNPs.
- Trial name
- NCT05125432
- Testing
- Acupuncture group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Affiliated Hospital of Qinghai University
Miscarriage
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
Abortion is one of the most common complications of pregnancy. Missed abortion is a type of abortions, occurs in 15%-20% of clinically diagnosed pregnancies and is defined as the retention of pregnancy products in the uterus for…
- Trial name
- NCT07109947
- Testing
- Letrozole 2.5mg
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Aswan University
Breast Cancer
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six…
- Trial name
- esozao (NCT01654367)
- Testing
- Zoledronic Acid and Aromatase Inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University
Musculoskeletal Pain
Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors
The primary objective of this trial is to assess the efficacy of targeted individualised physiotherapeutic treatment on aromatase inhibitor-associated musculoskeletal pain.
- Trial name
- AIMSS (NCT04560699)
- Testing
- Physiotherapeutic treatment and medical care, medical care
- Where
- Denmark
- Volunteers
- 111 people
- Sponsor
- Frederiksberg University Hospital
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Breast Cancer
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
Aromatase inhibitors are commonly prescribed for treatment of postmenopausal women with breast cancer. These medications can cause side effects in some women, and occasionally they can be quite bothersome.
- Trial name
- NCT01983995
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan
Breast Cancer
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
This randomized, open-label, two-arm, multi-center, Phase II study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor (AI) in first-line participants with HER2-positive…
- Trial name
- PERTAIN (NCT01491737)
- Testing
- Pertuzumab, Trastuzumab, Aromatase Inhibitor
- Where
- 82 sites in United States, Brazil and 6 more
- Volunteers
- 258 people
- Sponsor
- Hoffmann-La Roche
Periodontal Disease, Quality of Life
Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life.
- Trial name
- NCT01693731
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Cancer
An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
The purpose of this indirect treatment comparison (ITC) was to generate comparative evidence on the effectiveness and safety in premenopausal women of ribociclib+Non-steroidal Aromatase Inhibitor (NSAI)+Ovarian Function…
- Trial name
- IRINA (NCT07072013)
- Testing
- ribociclib
- Where
- Germany
- Volunteers
- 1,937 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Breast Cancer Females
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to…
- Trial name
- STRIVE-Chronic (NCT06776458)
- Testing
- N/A - Usual Care
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III breast cancer or who are at high risk for breast…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- AIMSS-RPS (NCT07443943)
- Testing
- Starch, Potato
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
The objective of this study is to compare the curative effects in patients under the age of 35 with hormone receptor positive breast cancer and high recurrent risk factors including large tumor or metastatic lymph nodes…
- Trial name
- ASPAIT (NCT02914158)
- Testing
- Goserelin, Tamoxifen, Aromatase Inhibitors
- Where
- 25 sites in China
- Volunteers
- 680 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia
Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy
Older women (≥65 years) with HR+ non-metastatic breast cancer experience high symptom burden and reduced quality of life during aromatase inhibitor (AI) therapy.
- Trial name
- GOAL-AI (NCT07232056)
- Testing
- GOAL-AI, CST-AI
- Volunteers
- 452 people
- Sponsor
- Duke University
Advanced Breast Cancer
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.
- Trial name
- NCT01311037
- Testing
- GnRh Analogue and Aromatase Inhibitor
- Where
- Saudi Arabia
- Volunteers
- 2 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Brest Cancer ER+ and HER2 Negative
De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen…
- Trial name
- DELTA (NCT07866430)
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Montefiore Medical Center
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network